Printer Friendly

Synthetic modified mRNA for reprogramming of human cells.

Abingdon, U.K.-based AMSBio announced the availability of highly modified synthetic 5-prime capped mRNA products for reprogramming of human cells.

These new ready-to-use products provide a simple, safe non-integrating methodology for reprogramming cell fate based on the administration of synthetic modified mRNA that greatly increases efficiency whilst reducing the innate antiviral response of viral protocols.

Clinical applications of induced pluripotent stem cells (iPSCs) have traditionally been limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically applicable cell types are not possible by viral methods.

AMSBio can provide ready-to-use highly modified mRNAs including Kfl4, c-Myc, Oct4, Sox2, LIN28 mRNA, and cGFP control, in customised formats for your research. These proven synthetic adaptations of 5-prime, 3-prime and internal mRNA structures enable reprogramming of multiple human cell types to pluripotency with conversion efficiencies that greatly surpass established methods. Furthermore this same technology can be used to efficiently direct the differentiation of mRNA-induced pluripotent stem cells into terminally differentiated cells and can be employed as an alternative to DNA-based gene therapy.

According to the company, die technology represents a safe, non-mutagenic and efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, tissue-engineering and regenerative medicine.

AMSBio offers a complete cell reprogramming service, from initial consultancy, synthesis of modified DNA, plasmid cloning, full DNA sequencing documentation, PCR amplification of inserts and characterization with subsequent RNA synthesis by in vitro transcription.

Contact: http://www.amsbio.com

COPYRIGHT 2011 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:New Products
Publication:Stem Cell Lab World
Date:Sep 12, 2011
Words:267
Previous Article:BioTime to develop vascular cells derived from hESCs.
Next Article:Advanced growth factor technology boosts biological activity.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters